Pegylated Interferon-Alpha Dosing for Myeloid Neoplasm Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for myeloproliferative neoplasms (MPNs) such as polycythemia vera, primary myelofibrosis, and essential thrombocythemia are limited by resistance or intolerance to hydroxyurea and anagrelide, and existing JAK inhibitors do not provide sufficient superiority over best supportive care in HU-resistant or intolerant ET patients.
Innovation Solution
Administration of pegylated interferon-α at regular intervals of every 2 to 8 weeks, with an initial dose of 250 to 500 μg, titrated to reach a target dose, as a conjugate of formula I, which includes a polymer moiety and an interferon-α moiety, to treat myeloid neoplasms, acute leukemia, or infectious diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hydroxyurea or anagrelide is used for cytoreduction in high-risk ET and PV patients, then thrombotic events are averted, but resistance or intolerance develops leading to poor prognosis
Solution Approach 1:
The patent changes the chemical structure parameter by using pegylated interferon-alpha conjugates with different molecular weights (20 kDa, 40 kDa, or 60 kDa PEG) instead of conventional small-molecule inhibitors, thereby achieving a different mechanism of action that overcomes resistance and intolerance to hydroxyurea and anagrelide
Solution Approach 2:
The patent creates a composite molecular structure by conjugating interferon-alpha with polyethylene glycol chains, forming a new therapeutic agent that combines the antiviral/antiproliferative properties of interferon with the extended circulation and reduced immunogenicity of PEGylation
2Reliability
If JAK inhibitor ruxolitinib is used as second-line therapy for PV, then effectiveness is achieved, but superiority over best supportive care is not demonstrated in HU-resistant or intolerant ET patients
Solution Approach 1:
The patent changes the therapeutic parameter by using interferon-based cytoreduction instead of JAK inhibition, targeting the upstream JAK-STAT pathway activation through a different mechanism that has demonstrated superiority in clinical trials for both PV and ET patients
Solution Approach 2:
The patent uses pegylated interferon-alpha as an intermediary agent that modulates the immune system and directly inhibits proliferation of malignant hematopoietic cells, thereby controlling MPN disease progression and cytopenias through a mediating mechanism distinct from direct JAK inhibition
3Productivity
If pegylated interferon-α is administered at higher doses more frequently, then hematological and molecular responses are enhanced, but safety and tolerability may be compromised
Solution Approach 1:
The patent optimizes the dosage parameter by administering pegylated interferon-alpha at 500 μg every two weeks (or 1000 μg every four weeks), achieving effective cytoreduction and molecular response while maintaining an acceptable safety profile through the extended half-life provided by PEGylation
Solution Approach 2:
The patent implements periodic dosing every two weeks or every four weeks instead of continuous daily administration, allowing the drug to accumulate to therapeutic levels while providing rest periods that reduce immunogenicity and adverse effects
Data Source
AI summary
Disclosed in a method of treating a myeloid neoplasm, acute leukemia, or infectious disease in a subject, the method including administering to a subject in need thereof a pegylated interferon-α at a regular interval of every 2 to 8 weeks at a first dose of 250 to 500 μg.